ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Galecto Inc

Galecto Inc (GLTO)

2.90
0.05
(1.75%)
Cerrado 27 Abril 3:00PM
2.83
-0.07
(-2.41%)
Fuera de horario: 6:59PM

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
2.90
Postura de Compra
2.83
Postura de Venta
3.21
Volume Operado de la Acción
41,718
2.80 Rango del Día 3.2248
2.01 Rango de 52 semanas 18.50
Capitalización de Mercado [m]
Precio Anterior
2.85
Precio de Apertura
2.80
Última hora de negociación
Volumen financiero
US$ 126,230
Precio Promedio Ponderado
3.0258
Volumen promedio (3 m)
263,049
Acciones en circulación
1,322,359
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.10
Beneficio por acción (BPA)
-29
turnover
-
Beneficio neto
-38.35M

Acerca de Galecto Inc

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Galecto Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLTO. The last closing price for Galecto was US$2.85. Over the last year, Galecto shares have traded in a share price range of US$ 2.01 to US$ 18.50.

Galecto currently has 1,322,359 shares in issue. The market capitalisation of Galecto is US$3.77 million. Galecto has a price to earnings ratio (PE ratio) of -0.10.

GLTO Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.4719.3415637862.432.86212.36357342.69940497CS
4-0.4-12.12121212123.33.532.01381542.76997909CS
12-2.04-41.29554655874.947.32.012630495.88683561CS
26-4.3-59.72222222227.27.592.011349315.87483437CS
52-14.22-83.060747663617.1218.52.0115354610.03142511CS
156-44.85-93.926701570747.7592.52.0119569423.56314433CS
260-391.35-99.2644261256394.25449.752.0122379571.16180944CS

GLTO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Galecto?
El precio actual de las acciones de Galecto es US$ 2.90
¿Cuántas acciones de Galecto están en circulación?
Galecto tiene 1,322,359 acciones en circulación
¿Cuál es la capitalización de mercado de Galecto?
La capitalización de mercado de Galecto es USD 3.77M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Galecto?
Galecto ha negociado en un rango de US$ 2.01 a US$ 18.50 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Galecto?
El ratio precio/beneficio de Galecto es -0.1
¿Cuál es la moneda de reporte de Galecto?
Galecto presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Galecto?
El último beneficio anual de Galecto es USD -38.35M
¿Cuál es la dirección registrada de Galecto?
La dirección registrada de Galecto es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Galecto?
La dirección del sitio web de Galecto es www.galecto.com
¿En qué sector industrial opera Galecto?
Galecto opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WWWW International Inc
US$ 0.395
(167.62%)
223.58M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M
GREEGreenidge Generation Holdings Inc
US$ 1.3197
(53.92%)
5.84M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.28
(44.30%)
38.04M
CGTLCreative Global Technology Holdings Ltd
US$ 1.5197
(-75.09%)
3.88M
TOIIWOncology Institute Inc
US$ 0.1015
(-40.22%)
156.14k
COEPCoeptis Therapeutics Holdings Inc
US$ 7.70
(-38.25%)
716.99k
INTSIntesity Therapeutics Inc
US$ 0.56
(-37.78%)
3.21M
SMMTSummit Therapeutics Inc
US$ 23.47
(-36.05%)
24.67M
GNLNGreenlane Holdings Inc
US$ 0.012699
(-15.34%)
355.22M
AGMHAGM Group Holdings Inc
US$ 0.0477
(22.31%)
340.91M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.455
(19.62%)
266.95M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M

GLTO Discussion

Ver más
swingforthe fence swingforthe fence 1 mes hace
Got in at $5.21 Friday
👍️0
swingforthe fence swingforthe fence 1 mes hace
Let Go Get It GLTO
👍️0
Mr. Zen Mr. Zen 1 mes hace
Is this still accurate?, if it is you have a time bomb on your hands. Easy double would just be a start.

Outstanding Shares
1,316,989
10/30/2024
👍️0
Retire43 Retire43 6 meses hace
GALT MENTIONED IN THIS ARTICLE.

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda
👍️0
Retire43 Retire43 7 meses hace
Please watch this and comment your opinion

👍️0
Monksdream Monksdream 8 meses hace
GLTO under $15
👍️0
Retire43 Retire43 10 meses hace
BIXT:

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️0
Retire43 Retire43 11 meses hace
Share this.


https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
👍️0
Retire43 Retire43 11 meses hace
Share this news with everyone, you know

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax
👍️0
Retire43 Retire43 12 meses hace
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

👍️0
Retire43 Retire43 1 año hace
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
👍️0
Retire43 Retire43 1 año hace
https://www.zerohedge.com/news/2023-12-12/disease-x-resistance-futile
👍️0
TrendTrade2016 TrendTrade2016 2 años hace
glto on the move
👍️0
subslover subslover 2 años hace
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.

In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.

Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary.

As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.
👍️0
Retire43 Retire43 2 años hace
Please share this!

Science buff #Investor #vaccinated #unvaccinated #COVID19 #LongCovid #Covid #masks #masksdontwork we want all to hear about a new paradigm in #drug development. $BIXT @buffalofireside talk about #galectin #drugs & potent #antiviral https://t.co/vma2hIy6CY @EnemyInAState pic.twitter.com/ARIwmsS65t— Mike Sheikh (@MikeSheikh2) September 20, 2023
👍️0
Retire43 Retire43 2 años hace
Look at this Reprint. Share this !

https://www.preprints.org/manuscript/202309.0077/v1
👍️0
Retire43 Retire43 2 años hace
https://www.zerohedge.com/news/2023-09-12/mask-mandates-unpopular-due-existence-next-gen-antivirals-pipeline
👍️0
Retire43 Retire43 2 años hace
Did anyone catch this today ?

H.C. Wainwright 25th Annual Global Investment Conference

Date: Monday, September 11, 2023
Time: 7:00 am ET
Location: New York City, NY
👍️0
Butchmass Butchmass 2 años hace
When is this company going to start doing more to publicize itself. They could be more up front and active with the share holders.
👍️0
Triple nickle Triple nickle 2 años hace
Added a few down here
👍️0
Monksdream Monksdream 2 años hace
Damn shame
Sold quite a while ago at a profit
👍️0
TheFinalCD TheFinalCD 2 años hace
$GLTO (.80) -65% Galecto to discontinue development of lung disease treatment
Reuters
Tue, August 15, 2023 at 7:35 AM EDT

Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)

https://finance.yahoo.com/news/galecto-discontinue-development-lung-disease-113556937.html
👍️0
Monksdream Monksdream 2 años hace
GLTO now ;No 11; on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 2 años hace
GLTO new 52/week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Butchmass Butchmass 2 años hace
Monksdream, I hope we see considerable more traffic on this board soon. Earnings coming out 7/28/2023.
👍️0
Monksdream Monksdream 2 años hace
GLTO No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Su Consulta Reciente

Delayed Upgrade Clock